Duchenne muscular dystrophy
RSS feedLack of benefit of tamoxifen confirmed in non-marching DMD patients
The results of the second part of the tamoxifen trial focused on non-marching Duchenne muscular dystrophy (DMD) patients, aged between 10 and 16 years, who had not received corticosteroid treatment for at least six months. In this group, 8 participants received tamoxifen (20 mg/day) and 6 a placebo for one year. The international trial included … [Read more]
A meta-analysis of the efficacy and safety of vamorolone in DMD
German clinicians have compiled data from the literature in order to assess the efficacy and safety of vamorolone, a new-generation synthetic corticosteroid recently authorised in Europe and the United States to treat Duchenne muscular dystrophy (DMD): data from 210 DMD patients treated with vamorolone at a dose of 2 mg/kg/day or 6 mg/kg/day were collected … [Read more]
The first digital functional assessment tool validated in DMD
The international consortium of researchers, including experts from the Institute of Myology, which developed SV95C, a digital parameter for the functional evaluation of Duchenne muscular dystrophy (DMD), has announced its adoption by the European Medicines Agency (EMA) as a primary endpoint in therapeutic trials: this assessment is based on the analysis of information transmitted by … [Read more]
DMD: a summary of the factors correlated with cardiac damage
A review of the literature on predictors of cardiac involvement in Duchenne muscular dystrophy included 33 articles concerning 9,232 patients. Most (76%) were retrospective studies, 15% randomised studies, 6% prospective cohort studies and 3% case series. Cardiac treatments were significantly associated with preserved systolic ejection fraction, with a moderate to high level of evidence. Mutations … [Read more]
Viltolarsen slows the decline in respiratory function in walking and non-walking patients
A drug targeting exon 53 skipping of the DMD gene authorised in the United States and Japan, viltolarsen was evaluated for 48 weeks (80mg/kg/week) in 10 walking and 10 non-walking DMD patients aged 8 and over, in the Galactica53 trial. The results compared with those of untreated DMD patients from an external cohort showed that … [Read more]
DMD: French recommandations on corticoids
On the basis of a review of the literature, the Filnemus neuromuscular rare diseases health network and the French Paediatric Neurology Society (SFNP), including clinicians from I-Motion, have published recommendations to harmonise practices for prescribing corticosteroid therapy and monitoring associated adverse effects in children with Duchenne muscular dystrophy. With regard to the long-term use of … [Read more]
A study of the relationship between ambulation loss and the impact of corticosteroids on growth in DMD
The UK consortium dedicated to Duchenne muscular dystrophy (DMD) reports the results of a retrospective study designed to investigate a possible link between the side-effects of long-term steroid administration on weight and height curves and the age of loss of ambulation: the clinical and anthropometric data of 648 children with DMD selected from the UKNorth … [Read more]
Towards a better understanding of genotype/phenotype correlations in DMD
American clinicians studied a large cohort of children followed at the only neuromuscular consultation in Cincinnati (USA) for Duchenne muscular dystrophy (DMD): 555 patients were included in the study, All were receiving long-term corticosteroid therapy (at least 12 months), but without any associated innovative therapy, age at loss of walking was chosen as the main … [Read more]
A multi-factorial approach to urinary disorders in DMD
Turkish physiotherapists report on their experience in assessing symptoms, disorders and signs of the lower urinary tract in children with Duchenne muscular dystrophy (DMD): 45 children and adolescents aged 5-18 years with DMD were included in the study, Assessments included a functional score assessing bladder emptying and the risk of urinary incontinence, a Vignos score, … [Read more]
Comparative data on vamorolone and prednisone for adrenal suppression
Long-term corticosteroid therapy remains the reference treatment for Duchenne muscular dystrophy (DMD), but is associated with numerous side-effects, including resting of the hypothalamo adrenal axis. An international group of researchers has carried out a post-hoc analysis of the data obtained in a previous phase IIb trial designed to demonstrate the superiority of vamorolone (a new-generation … [Read more]
